Background
KRAS, NRAS and HRAS are functionally and structurally close proto-oncogenes with conserved sequences at important functional regions. Mutated Ras family members promote oncogenesis, cause cell proliferation and survival and confer resistance to anti-EGFR therapy. We hypothesized Ras family mutations have variable molecular and clinical features including in metastasis of CRC.